SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing

Cambridge, Massachusetts, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. NASDAQ:PMN, a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial…

PMN

Related stories